CSIMarket
 


Erytech Pharma S a   (ERYP)
Other Ticker:  
 
 

ERYP's Income from Cont. Operations Growth by Quarter and Year

Erytech Pharma S A 's Income from Cont. Operations results by quarter and year




ERYP Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December -0.26 -60.25 -82.10 -70.18
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   -0.26 -60.25 -82.10 -70.18



ERYP Income from Cont. Operations fourth quarter 2022 Y/Y Growth Comment
Erytech Pharma S a in the fourth quarter 2022 recorded loss from continued operations of $ -0.26 millions.

According to the results reported in the fourth quarter 2022, Erytech Pharma S A achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Erytech Pharma S A ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2022.




ERYP Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Erytech Pharma S A 's fourth quarter 2022 Income from Cont. Operations $ -0.26 millions ERYP's Income Statement
Erytech Pharma S A 's fourth quarter 2021 Income from Cont. Operations $ -60.25 millions Quarterly ERYP's Income Statement
New: More ERYP's historic Income from Cont. Operations Growth >>


ERYP Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Erytech Pharma S A 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ERYP's IV. Quarter Q/Q Income from Cont. Operations Comment


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ERYP's IV. Quarter Q/Q Income from Cont. Operations Comment


Erytech Pharma S A 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
0
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -0.26 $ 0.00 $ 0.00 $ 0.00 $ -60.25
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment


Erytech Pharma S a achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Erytech Pharma S a achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
ERYP's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for ERYP's Competitors
Income from Cont. Operations Growth for Erytech Pharma S A 's Suppliers
Income from Cont. Operations Growth for ERYP's Customers

You may also want to know
ERYP's Annual Growth Rates ERYP's Profitability Ratios ERYP's Asset Turnover Ratio ERYP's Dividend Growth
ERYP's Roe ERYP's Valuation Ratios ERYP's Financial Strength Ratios ERYP's Dividend Payout Ratio
ERYP's Roa ERYP's Inventory Turnover Ratio ERYP's Growth Rates ERYP's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2022
Halozyme Therapeutics Inc -1.29%$ -1.293 millions
Inmode Ltd -2.15%$ -2.153 millions
Vanda Pharmaceuticals Inc -3.07%$ -3.066 millions
Iradimed Corporation-5.63%$ -5.627 millions
Polypid Ltd -7.15%$ -7.145 millions
Amedisys Inc -7.24%$ -7.245 millions
Biontech Se-8.34%$ -8.337 millions
Lemaitre Vascular Inc -8.87%$ -8.874 millions
Alcon inc -10.90%$ -10.904 millions
Merck and Co Inc -11.10%$ -11.101 millions
Acadia Healthcare Company Inc -11.71%$ -11.709 millions
Intuitive Surgical Inc -12.02%$ -12.020 millions
Eton Pharmaceuticals Inc -12.22%$ -12.223 millions
Steris Plc-13.82%$ -13.815 millions
Pharming Group N v -14.52%$ -14.516 millions
Integer Holdings Corporation-14.55%$ -14.554 millions
Bristol myers Squibb Company-14.63%$ -14.629 millions
Amgen Inc -14.90%$ -14.903 millions
Stryker Corp-14.95%$ -14.955 millions
Exagen Inc -15.49%$ -15.489 millions
Zynex inc -16.21%$ -16.213 millions
Uniqure N v -17.07%$ -17.069 millions
Qiagen N v -17.44%$ -17.438 millions
Chemed Corporation-21.27%$ -21.266 millions
Rapid Micro Biosystems Inc -22.31%$ -22.312 millions
Baxter International Inc -23.55%$ -23.554 millions
Becton Dickinson And Company-24.93%$ -24.926 millions
Encompass Health Corporation-26.45%$ -26.448 millions
Fresenius Medical Care Ag-26.64%$ -26.636 millions
Redhill Biopharma Ltd -26.68%$ -26.677 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com